About Orakl Oncology
Orakl Oncology is a company based in Villejuif (France) founded in 2023 by Diane-Laure Pages, Gustave Ronteix, and Fanny Jaulin. Orakl Oncology has raised $14.7 million across 2 funding rounds from investors including Speedinvest, Bpifrance and HCVC. Orakl Oncology offers products and services including Precision Medicine Services. Orakl Oncology operates in a competitive market with competitors including Oncodesign, LumaBridge, Lytica Therapeutics, Orange Grove Bio LLC and Axios Biosciences, among others.
- Headquarter Villejuif, France
- Founders Diane-Laure Pages, Gustave Ronteix, Fanny Jaulin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orakl Oncology Sas
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.7 M (USD)
in 2 rounds
-
Latest Funding Round
$11.56 M (USD), Seed
Dec 03, 2024
-
Investors
Speedinvest
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orakl Oncology
Orakl Oncology offers a comprehensive portfolio of products and services, including Precision Medicine Services.
Services to accelerate oncology drug development through partnerships
Funding Insights of Orakl Oncology
Orakl Oncology has successfully raised a total of $14.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $11.56 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orakl Oncology
Orakl Oncology has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Speedinvest, Bpifrance and HCVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital investments are made in European startups.
|
Locked | Locked | Locked | |
|
Early-stage venture capital and startup acceleration are provided.
|
Locked | Locked | Locked | |
|
Investments are directed toward hard-tech and full-stack companies by HCVC.
|
Locked | Locked | Locked |
Investor details for Orakl Oncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orakl Oncology
Investment portfolio details for Orakl Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orakl Oncology
Detailed financials for Orakl Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orakl Oncology Comparisons
Peer comparison for Orakl Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orakl Oncology
Orakl Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncodesign, LumaBridge, Lytica Therapeutics, Orange Grove Bio LLC and Axios Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Preclinical assessment services for anti-cancer therapies are provided.
|
|
| Locked | Locked | Locked |
Provider of oncology clinical research, regulatory affairs, and data management services
|
|
| Locked | Locked | Locked |
Therapeutic drugs are developed for medical applications.
|
|
| Locked | Locked | Locked |
Provider of preclinical development services
|
|
| Locked | Locked | Locked |
Creates innovative platforms for anti-cancer drug development.
|
Detailed competitors of Orakl Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orakl Oncology
Complete news archive for Orakl Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orakl Oncology
Orakl Oncology was founded in 2023.
Orakl Oncology is headquartered in Villejuif, France.
Fanny Jaulin is the current CEO of Orakl Oncology. They have also founded this company.
Orakl Oncology is a funded company, having raised a total of $14.7M across 2 funding rounds to date.
Orakl Oncology is a precision oncology start-up that partners with Gustave Roussy, one of the worlds top cancer centers, to connect patient tumors and enable the emergence of rare oncology. They have recently raised 3 million to develop their techbio platform for precision oncology.
Orakl Oncology's top competitors include Oncodesign, Lytica Therapeutics and Orange Grove Bio LLC.
Orakl Oncology offers Precision Medicine Services.
Orakl Oncology has 5 investors. Key investors include Speedinvest, Bpifrance, HCVC, Singular, and Verve Ventures.